There are controversial reports suggesting that IL-18 promoter polymorphisms may be an independent marker of RA susceptibility. The aim of the present study was to determine whether polymorphisms of the IL-18 gene promoter in positions -607 (rs 1946519) and -656 (rs 1946518) 
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic inflammatory disease, characterised by chronic synovitis and progressive joint destruction. The etiology of RA is multifactorial and includes a significant genetic component. Cytokines act as mediators of immune and inflammatory responses and play an important role in the pathophysiology of joint inflammation and destruction (Feldmann et al., 1996) . A central feature of RA is a relative imbalance of cytokine production with a relative excess of proinflammatory molecules, compared with antiinflammatory mediators (Feldmann et al., 1996) . It has been observed that the production of proinflammatory cytokines is markedly increased in serum and synovial fluid in RA patients. The expression levels of cytokines have a genetic background. Single nucleotide polymorphisms (SNPs), the most common genetic variations that have been identified in the cytokine genes promoter, may be responsible for variations in cytokine production. The successful therapeutic use of inhibitors of proinflammatory cytokines (TNF-a, IL-6) underlines the importance of these molecules in driving rheumatoid inflammation and tissue damage. However, non-responder or partial responder patients are not uncommon, and inflammatory disease can flare on discontinuation of treatment. Therefore, new therapeutic targets in RA should be investigated.
Interleukin 18 (IL-18), a member of the IL-1 superfamily, was first identified as an interferon-g (IFN-g) inducing factor (Okamura et al., 1995) . It is widely expressed in human tissues (Dinarello et al., 1998) . IL-18 in RA is produced predominantly by tissue macrophages (Gracie et al., 1999; Tanaka et al., 2001; Yamamura et al., 2001) . In addition, mature IL-18 may also be released from dendritic cells (Gardella et al., 1999) , neutrophils (Westphal et al., 2006) and endothelial cells (Yamaoka-Tojo et al., 2003) .
IL-18 has a highly diverse range of biological function. IL-18 induces the synthesis of TNF-a, granulocyte-macrophage colony stimulating factor, nitric oxide, and chemokines by T cells and natural killer cells (Dinarello, 1999) . IL-18 directly activates synovial macrophages, promotes production of proinflammatory cytokines such as TNF-a and IL-1b (Gracie et al., 1999) , induces the production of hemokines and expression of adhesion molecules by synovial fibroblasts 2002) , and stimulates angiogenesis . IL18 indirectly stimulates osteoklastogenesis through upregulation of membrane bound receptor activator of NFkB ligand (RANKL) production from RA synovial T cells or through induction of TNF-a, IL-1b and IL-6 (Dai et al., 2004) .
IL-18 has been found in synovial tissue, and enhanced levels of IL-18 were observed in the serum and in the joint of RA patients (Gracie et al., 1999) . Serum and synovial fluid IL-18 levels as well as synovial tissue IL-18 expression were correlated with disease activity parameters (erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), and Disease Activity Score (DAS 28) ) (Yamamura et al., 2001; Joosten et al., 2003; Rooney et al., 2004; Petrovic-Rackov et al., 2006) .
The IL-18 gene maps to chromosome 11q22.2-q22.3 (Nolan et al., 1998) . Several single-nucleotide polymorphisms (SNPs) in the promoter region in the IL-18 gene are present, which may affect IL-18 expression. Allelic variants of cytokine genes associated with promoter gene region polymorphisms do not influence the protein amino acid sequence but can result in changes of cytokine production. The -607 C/A SNP is located at the binding sites for CREB transcriptional factors (cAMP response-element binding proteins), and therefore, mutations at this site can influence IL-18 expression and change the production of the cytokine (Giedraitis et al., 2001) .
The aim of the present study was to examine two IL-18 gene SNPs in positions -607 (rs 1946519) and -656 (rs 1946518) in the promoter region in relation to the RA susceptibility, activity and severity.
MATERIALS AND METHODS

Patient population.
A total of 105 patients with established RA (women and men) according to the well-known revised criteria of the American College of Rheumatology (ACR) for RA (Arnett et al., 1988) were consecutively recruited into the study during a one-year period. Patients with RA were recruited from the outpatient and inpatient populations in the Rheumatology Department Clinic "Linezers", Rîga Eastern Hospital, Latvia. Informed consent was obtained from all patients.
Evaluation of the patients included a physical examination with a particular focus on the pattern of joint involvement and laboratory analyses. The following data were obtained from the RA patients: age of disease onset, number of tender (TEN) and swollen (SW) joints, visual analogue scale (VAS) of pain and disease activity, physician assessment of disease activity, presence and value of rheumatoid factor (RF) and anti-cyclic-citrullinated peptides (antiCCP) antibodies, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and rentgenological (RTG) stage. The modified disease activity score DAS28 was calculated as described (Prevoo et al., 1995) . Simple x-rays of the hands and feet were analysed using the Steinbrocker method (Pincus et al., 1997) . Within the RA group, eight patients lacked evidence of joint erosions on the radiograph (stage I: nonerosive RA) and 97 patients had erosions (stages II-IV: erosive RA; 19 -stage II, 75 -stage III, and 3 -stage IV). Demographic, clinical, and laboratory characteristics of RA patients are summarised in Table 1. A total of 242 healthy subjects with similar age and sex distribution were available for the study from Genome Database of Latvian Population (median 53, range 17-84 years, female 195 (81.3%), male 45 (18.8%)).
Genetic analysis. Genotypes were obtained by direct sequencing. Analysis of SNPs at the -607 and -656 positions of the IL-18 gene were studied.
Genomic DNA was extracted from peripheral blood samples using the standard phenol-chloroform extraction method. The IL18 promoter region harbouring SNPs at positions -607 and -656 was PCR amplified using forward 5'-ATTCAGGACTTCCCCTTCCT-3' and reverse 5'-CACTCTGCTCTTCAAACGTTACAT -3' primers. Amplicons were then purified using Sap-ExoI protocol and the sequences were obtained by direct sequencing of amplified products using forward PCR primer on a 3100 ABI prism DNA sequencer (Applied Biosystems). The following PCR mix and conditions were used. PCR mix per sample contained 15 mkl of 2x PCR Master Mix (Fermentas Life Sciences, Lithuania), forward and reverse primers (1 mM) and 28 ng of dried genomic DNA. The cycling conditions for PCR were: 5 minutes of initial denaturation at 95°C, followed by 32 cycles of 15 seconds at 95°C, 30 seconds at 56°C, 30 seconds at 72°C, and final extension for 10 minutes at 72°C.
Statistical analysis.
The chi-squared test was used for the calculation of the deviation from the Hardy-Weinberg equilibrium. Fisher's exact test and chi-square tests was used to examine allele/genotype association with presence of RA and other qualitative variables (positive RF, anti CCP and others). Dichotomised variables were created for RF and anti-CCP levels (for RF positivity 14 IU/ml; for antiCCP positivity > 5.0 units/ml). ANOVA tests was used to compare quantitative variables (age at onset of RA, VAS, DAS28, SW28, TEN28, CRP, ESR) between genotype-stratified subgroups of RA patients. A P value less than 0.05 was considered statistically significant. Odds ratios (OR) were calculated with a 95% confidence interval (CI). All statistics were conducted using the software package SPSS, version 13.0.
RESULTS
All genotyping results fit Hardy-Weinberg equilibrium. The distribution of alleles and genotypes is shown in Table 2 .
There were no significant differences in the distribution of the IL-18 gene alleles and genotypes between RA patients and the control group, but we found a difference in the frequencies of IL-18-607C/A and -656G/T genotypes, not alleles, between RA patients and the control group in women (Table 3) .
We found a significant difference between frequencies of heterozygous versus homozygous genotypes; heterozygous genotypes -607CA and -656GT occurred more frequently in the RA group than in the control (Table 4) . This difference was even larger when only women were considered (Table  5 ).
There were no differences in marker distributions between RA patients and the control for different age groups, men and control groups (data not shown). There were no differences found between age of onset RA, disease activity parameters (ESR, CRP, DAS28, SW28, TEN28), antibody status (RF positive/negative; antiCCP positive/negative), and RTG stages in RA group (data not shown).
DISCUSSION
In the present study we examined SNPs at the -607 and -656 positions of the IL-18 gene in the patients with RA, in relation to disease susceptibility, activity and severity.
We found a significant difference in between RA patients and the control group in the distribution of heterozygous versus homozygous genotypes. A significant difference was also found when only the respective women groups were examined. Reports evaluating the role of IL-18 promoter polymorphisms in RA patients have shown variable results for different SNPs. Sivalingam et al (2003) found that controls had significantly higher frequency of the AA genotype at position -607 when compared to RA patients and concluded that the AA genotype at position -607 is associated with a protective effect against development of RA in Chinese individuals. Rueda et al. (2005) observed no statistically significant differences between RA patients and controls in allelic and genotypic frequencies of -607C/A and -137C/G IL-18 promoter polymorphisms. In addition, no association was found with the haplotypes inferred by the two polymorphisms and RA susceptibility. RA patients were stratified according to sex, age at the onset of the disease rheumatoid factor status, and extraarticular manifestations and no association was found with these polymorphisms. Therefore, the conclusion is that studied polymorphisms within the IL-18 promoter region do not play a major role in RA predisposition. Gracie et al. (2005) found that the -607C/-137C haplotype was more prevalent in Caucasian RA patients than in a control group and concluded that SNP of both positions contribute to the genetic background of RA pathogenesis. Lee et al. (2007) reported a significantly higher frequency of the 105A allele of the IL-18-105A/C SNP in Chinese rheumatoid arthritis patients compared with controls. The relative risk of rheumatoid arthritis was stronger in 105A homozygotes. Sugiura et al. (2006) showed that 12 SNP within the promoter region of the IL-18 gene were associated with susceptibility to juvenile idiopathic arthritis (JIA) in Japanese patients. There was a strong association between the diplotype configuration of S01/S01 of the IL-18 gene and JIA. T at position -656, A at position -607, and G at position -137 were the components of haplotype S01.
In the recent study by Pawlik et al. (2009) , where seven IL-18 gene SNPs were studied, no significant differences were found in the distributions of the genotypes except for rs360722 and haplotypes between RA patients and a control group. Age at RA diagnosis was lower in carriers of the -607 CC and rs187238 GG genotypes. Erosive disease was diagnosed more frequently in patients with the -607 CC and AC genotypes than in AA homozygotes.
A possible explanation for the discordant results could be linkage with other polymorphisms within the gene or within other genes; another one might be the variation of genetic susceptibility between ethnic groups (Burchard et al., 2003) . Allelic heterogeneity exists between ethnic groups, and different variations within the same gene can contribute to disease risk (Colhoun et al., 2003) .
It is well known that gene promoter polymorphisms can affect the level of protein production. The gene sequence can be associated with a cytokine phenotype. Homozygotes for the high-producer allele are the highest producers of the cytokine, homozygotes for the low-producer allele are the lowest producers of the cytokine and heterozygotes are intermediate. On the other hand, we can assume that homozygotes for the allele are the lowest producers of the cytokine and heterozygotes are the highest producers of the cytokine. Khripko et al. (2008) Values are given as number (%)
Odds ratio and the confidence interval at the 95% confidence level is indicated as OR and 95%CI, respectively those carrying the CA genotype at the -607 position, compared with donors with the -607CC genotype.
RA is one of many autoimmune diseases that is predominant in women, as it has a female-to-male ratio 2:1 to 3:1. Sex hormones can have significant effects on the cells known to participate in RA. However, the specific mechanisms responsible for increased susceptibility to RA in women are uncertain. Padyukov et al. (2004) showed an association of IL10 -1087 genotypes in woman with RA compared with men and controls. The observed difference in frequencies of alleles and genotypes of the IL-18 gene in positions -607 and -656 between RA patients and the control group in women suggests that RA in woman is a different disease subset. Further studies are needed and using a larger patient group, covering all rheumatology departments in Latvia. Patients should be enrolled based on the same inclusion criteria and with similar phenotypic data as used in the present study.
In conclusion, heterozygous states CA and GT at positions -607 and -656, respectively, of IL-18 gene may influence susceptibility to RA. More studies on a larger patient group is needed, to explore this association in Latvian population. On the basis of the investigated IL-18 polymorphisms, female patients with RA seem to represent a separate disease subgroup.
